Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 685Carcinoma, Non-Small-Cell Lung 328Neoplasms 170Breast Neoplasms 166Lung Neoplasms 158Urinary Bladder Neoplasms 157Neoplasm Metastasis 140Cholangiocarcinoma 113Ovarian Neoplasms 106Biliary Tract Neoplasms 95Lymphoma, Large B-Cell, Diffuse 73Nasopharyngeal Carcinoma 71Lymphoma 66Sarcoma 63Recurrence 62Gallbladder Neoplasms 61Carcinoma, Transitional Cell 56Triple Negative Breast Neoplasms 54Hodgkin Disease 52Colorectal Neoplasms 49Lymphoma, Non-Hodgkin 48Fallopian Tube Neoplasms 48Adenocarcinoma 45Bile Duct Neoplasms 40Carcinoma, Ovarian Epithelial 31Non-Muscle Invasive Bladder Neoplasms 30Uterine Cervical Neoplasms 28Carcinoma 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma of Lung 27

Interventions

pemigatinib 6infigratinib 3erdafitinib 2derazantinib 2Rogaratinib 2pembrolizumab 1lenvatinib 1exemestane 1brivanib 1atezolizumab 1Rabeprazole 1Irinotecan 1INCB 54828-101 1Gemcitabine 1Fulvestrant 1E-3810 1Drug Combinations 1Carboplatin 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Acrocephalosyndactylia × Gemcitabine × Clear all
NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Incyte Corporation

Phase 2 Terminated
7 enrolled 10 charts
Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡